Cipher Pharmaceuticals Reports Second Quarter 2019 Financial Results

Friday, August 9, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

 (IN THOUSANDS OF U.S. DOLLARS) 

Three months ended June 30, 2019

Three monthsended June 30, 2018

Six months

 ended June 30, 2019

Six months

ended 

June 30, 2018

$

$

$

$

Income from continuing operations

1,359

1,915

2,175

964

Add back:

Depreciation and amortization

310

166

609

391

Interest expense, net

221

153

443

283

Income taxes

478

927

901

786

EBITDA

2,368

3,161

4,128

2,424

Change in fair value of derivative financial instrument

(3)

(121)

(15)

(442)

Restructuring costs

660

660

Loss (gain) from the translation of Canadian cash balances

(37)

34

(63)

75

Impairment of intangible assets

1,832

Share-based compensation

37

246

69

403

Adjusted EBITDA

3,025

3,320

4,779

4,292



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store